Rarity Bioscience Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
30
- Latest Deal Type
-
Later Stage VC
- (Upcoming)
- Latest Deal Amount
-
$20M
- Investors
-
5
Rarity Bioscience General Information
Description
Developer of molecular amplification technology designed to detect small amounts of DNA sequence variants. The company's platform uses an ultrasensitive multiplex assay for detecting rare nucleic acid sequences in biological samples like liquid biopsies, enabling physicians with technology for research as well as clinical applications.
Contact Information
Website
www.raritybioscience.comCorporate Office
- Dag Hammarskjölds Väg 56E
- 752 37 Uppsala
- Sweden
Corporate Office
- Dag Hammarskjölds Väg 56E
- 752 37 Uppsala
- Sweden
Rarity Bioscience Timeline
Rarity Bioscience Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC | $20M | Upcoming | Product Development | |||
| 4. Early Stage VC | 18-Jun-2024 | Completed | Product Development | |||
| 3. Seed Round | 01-Dec-2022 | Completed | Product Development | |||
| 2. Angel (individual) | 12-Jul-2021 | $1.76M | $1.76M | Completed | Startup | |
| 1. Accelerator/Incubator | Completed | Startup |
Rarity Bioscience Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 15,000 | $94.71 | $94.71 | 1x | $94.71 | 20.4% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Rarity Bioscience Patents
Rarity Bioscience Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202506768-D0 | Detection of srca products by flow cytometry | Pending | 02-May-2025 | ||
| WO-2026229595-A1 | Detection of srca products by flow cytometry | Pending | 02-May-2025 | ||
| EP-4677110-A1 | Improved method for detecting a target variant base using a variant-specific probe | Pending | 08-Mar-2023 | ||
| GB-202303359-D0 | Improved method for detecting a target variant base using a variant-specific probe | Inactive | 08-Mar-2023 | ||
| US-20260242853-A1 | Improved method for detecting a target variant base using a variant-specific probe | Pending | 08-Mar-2023 | C12Q1/6827 |
Rarity Bioscience Signals
Rarity Bioscience Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Angel (individual) | Minority | |||
| Navigare Ventures | Venture Capital | Minority | ||
| Novalis Biotech | Venture Capital | Minority | ||
| UU Invest | Venture Capital | Minority | ||
| STUNS Life Science | Accelerator/Incubator | Minority |
Rarity Bioscience FAQs
-
When was Rarity Bioscience founded?
Rarity Bioscience was founded in 2021.
-
Where is Rarity Bioscience headquartered?
Rarity Bioscience is headquartered in Uppsala, Sweden.
-
What is the size of Rarity Bioscience?
Rarity Bioscience has 30 total employees.
-
What industry is Rarity Bioscience in?
Rarity Bioscience’s primary industry is Other Devices and Supplies.
-
Is Rarity Bioscience a private or public company?
Rarity Bioscience is a Private company.
-
What is Rarity Bioscience’s current revenue?
The current revenue for Rarity Bioscience is .
-
How much funding has Rarity Bioscience raised over time?
Rarity Bioscience has raised $11.7M.
-
Who are Rarity Bioscience’s investors?
, Navigare Ventures, Novalis Biotech, UU Invest, and STUNS Life Science have invested in Rarity Bioscience.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process